COLL Q4 2021 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$27M-64.1% YoY

Gross Profit

-$1M-4.9% margin

Operating Income

-$34M-124.7% margin

Net Income

-$25M-91.5% margin

EPS (Diluted)

$-0.73

QoQ Revenue Growth

-65.3%

Cash Flow

Operating Cash Flow

$36M

Free Cash Flow

$36M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$692M

Total Liabilities

$489M

Stockholders' Equity

$203M

Cash & Equivalents

$186M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$76M	-64.1%
Gross Profit	-$1M	$44M	-103.0%
Operating Income	-$34M	$15M	-327.5%
Net Income	-$25M	$7M	-459.8%

Revenue Segments

Nucynta IR

$13M60%

Nucynta ER

$9M40%